Pfizer Inc announced on Monday that its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study of adolescents aged 12 to 15 years.
According to the company, a two-dose series of the vaccine was 100 percent effective against COVID-19 from seven days to more than four months after the second dose.
Long-term data will be used to support planned submissions for full regulatory approval of the vaccine in the age group in the United States and around the world.
Pfizer and BioNTech will seek approval for a vaccine dose of 30 micrograms for people aged 12 and up.
The US Food and Drug Administration approved the vaccine for emergency use in people aged 12-15 years in May, and full approval for use in people aged 16 and up in August.